Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20199464 | 0.84 | GSK3A (0.42) | IRAK4KDM4EL3MBTL1GSK3AHTT | |
| SCHEMBL946897 | 0.77 | IRAK4 (0.68) | IRAK4KDM4EHTT | |
| SCHEMBL30521626 | 0.77 | IRAK4 (0.50) | IRAK4ADRA1AKDM4EPARP1MKNK1 | |
| SCHEMBL1420264 | 0.75 | MKNK1 (0.47) | IRAK4ADRA1AMAP2K1CLK4DYRK1B | |
| SCHEMBL31109663 | 0.75 | TGFBR1 (0.43) | IRAK4MAP2K1CLK4DYRK1BKDM4E | |
| SCHEMBL21331457 | 0.74 | ALDH1A1 (0.49) | KDM4EMAPTHPGDHSD17B10 | |
| SCHEMBL17303154 | 0.74 | HTT (0.55) | IRAK4GSK3AHTTMAPT | |
| Hydrochloric Acid SCHEMBL30521486 | 0.74 | MKNK1 (0.46) | IRAK4ADRA1AMAP2K1CLK4DYRK1B | |
| SCHEMBL11849070 | 0.74 | KDM4E (0.38) | IRAK4ADRA1AMAP2K1CLK4DYRK1B | |
| Hydrochloric Acid SCHEMBL31109907 | 0.73 | TGFBR1 (0.42) | IRAK4MAP2K1CLK4DYRK1BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110225912-B | GSK-3 inhibitors | 百时美施贵宝公司 | 2022-10-21 | — | — | CN | claimed |
| WO-2023151640-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| CN-110225912-B | GSK-3 inhibitors | 百时美施贵宝公司 | 2022-10-21 | — | — | CN | disclosed |
| US-8450354-B2 | Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110237570-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237570-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | BACE1, BACE2, PSEN1 | IRAK4 3666/4885ADRA1A 803/4885MAP2K1 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.